Biocon Biologics report explores pathways to increase biosimilar adoption in low- and middle-income countries Read more
Biocon Biologics refinances $ 1.1 bn long-term debt through USD bonds and new syndicated facility Read more
Biocon Biologics finalises agreement for Bmab 1200 market entry in Europe, UK, Canada, and Japan Read more